The PR "this evening" supports the C-19 EAP and phase 3 trial we have been discussing, but there's something new...So,this is a formal press release announcing the presentation by Dr.Grossman and colleagues at the recent ISCT meeting. A link to thepaper they presented is again here:
https://www.celltherapyjournal.org/article/s1465-3249(20)30570-3/fulltext
Note the part regarding COPD (sometimes calledemphysema): "These results support potential of remestemcel-L toeffectively treat inflammatory lung diseases, such as acutely decompensated COPD and ARDS." Note the "acutelydecompensated COPD" part. That strikes me as new. It suggeststhey plan to pursue that as a new, separate indication.
So,a COPD study run by Osiris about 10 years ago appears to be lendingsupport to the pursuit of both C-19 ARDS and now "inflammatorydecompensation of COPD", two indications we weren't thinking about atall just 2 months ago.
We can imagine COPD patients getting an infusion when their bronchitis flares or they develop "walking pneumonia". Or periodically just to maintain exercise tolerance if markers are elevated. Even an infusion once yearly is a huge market. Gravy on top of everything else.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.79 |
Change
0.065(3.77%) |
Mkt cap ! $2.291B | |||
| Open | High | Low | Value | Volume |
| $1.73 | $1.81 | $1.70 | $7.807M | 4.430M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 39187 | $1.79 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.81 | 12767 | 4 |
View Market Depth
| Last trade - 16.10pm 17/07/2025 (20 minute delay) ? |
| MSB (ASX) Chart |